Discovery and Molecular Targets - PowerPoint PPT Presentation

1 / 32
About This Presentation
Title:

Discovery and Molecular Targets

Description:

Tito Fojo Patrick O'Connor Yoshikazu Sugimoto. Albert Fornace Lawrence ... Steve Friend Marcus Peter George Vande Woude. Stanton Gerson Garth Powis David Waxman ... – PowerPoint PPT presentation

Number of Views:69
Avg rating:3.0/5.0
Slides: 33
Provided by: brian513
Category:

less

Transcript and Presenter's Notes

Title: Discovery and Molecular Targets


1
Discovery and Molecular Targets
  • Susan Holbeck, Ph.D.
  • National Cancer Institute
  • Developmental Therapeutics Program
  • Information Technology Branch
  • holbecks_at_mail.nih.gov

2
NCI-DTP Drug Discovery Resources
  • NCI panel of 60 human tumor cell lines
  • 2 day 5-dose growth inhibition assay
  • Molecular targets
  • 3 cell line high throughput prescreen
  • In vivo testing
  • Hollow fiber assay
  • Xenografts
  • Molecular targeted assays
  • RAND
  • Compounds, extracts, cell lines, and tumors

3
DTP Discovery Resources
  • RAND - (Rapid Access to NCI Discovery
  • Resources) - For academics and non-profits.
    Utilize for
  • analog or library synthesis, assay development
    assistance,
  • microarray technology, early formulation or PK/PD
    work
  • in order to select best candidate from multiple
    early
  • leads (Requires application and is peer-reviewed)
  • http//dtp.nci.nih.gov/docs/rand/rand_ind
    ex.html

4
Testing Compounds in the 60 Human Tumor Cell Line
Screen
  • Free of charge
  • Pure compounds and biologicals
  • Compound structures must be provided
  • Compounds can be covered by a confidentiality
    agreement, if desired
  • All screening data kept confidential for 2 years
  • Available to academics and companies
  • On-line submission form at http//dtp.nci.nih.gov
    /docs/misc/common_files/submit_compounds.html

5
Why Test in the 60 Cell Line Screen?
  • Information on tumor cell types affected by the
    compound
  • Information to help choose a lead compound
  • Qualifying compounds sent for in vivo hollow
    fiber testing
  • COMPARE can help suggest possible mechanisms

6
60 Cell Screen Endpoints
Adriamycin
50 growth inhibition
Total growth inhibition
50 lethality
GI50
LC50
TGI
7
Mean Graphs
8
Comparing Mean Graphs
Adriamycin
Daunorubicin
Oxanthrazole
Teniposide
9
COMPARE Finds Compounds With Similar 60 Cell
Activity
  • Compound PCC
  • Adriamycin 1.00
  • Daunorubicin 0.950
  • Deoxydoxorubicin 0.900
  • Teniposide 0.878
  • Oxanthrazole 0.864

10
Diverse Chemical StructuresSimilar Mechanism of
ActionSimilar Behavior in 60 Cell Screen
Correlation with Colchicine
Vincristine sulfate 0.67 Taxol
0.57 Maytansine 0.74 Nocodazole
0.64 Leurosine N-oxide 0.44 Rhizoxin
0.67 Dolastatin 10 0.45 Halichondrin B
0.59
11
COMPARE Can Help Develop Hypotheses
  • Start with a compound of known mechanism to find
    other structures to test for similar mechanism
  • Start with a compound of unknown mechanism - see
    if COMPARE can suggest a possible MOA

12
Compound COMPARE Success Stories
  • Paullones - a new class of CDK inhibitors
  • nM PKC ligands that correlate with phorbol esters
  • Novel inhibitors of the thioredoxin reductase
    pathway
  • Numerous novel tubulin binders and Topo
    interacting agents

13
DTP Molecular Targets
  • Definition
  • Measurement of molecular entities in the NCI 60
    human tumor cell line panel
  • Most measurements made by extramural researchers
  • Goals
  • Correlate patterns of anticancer compound
    activity with molecular target measurements
  • Identify cell lines with desired characteristics
  • Improve understanding of the target

14
Molecular Target Measurements
  • Enzyme activity measurements
  • e.g., DT-diaphorase, P450s
  • Gene mutation status
  • e.g., Ras, p53
  • Protein levels
  • e.g., Thymidylate synthase
  • mRNA levels
  • e.g., Microarray
  • Other
  • e.g., Phosphorylation status of a protein

15
Molecular Target Data in the 60 Cell Panel
  • Data is available from the DTP Web site
  • http//dtp.nci.nih.gov/mtargets/mt_index.html
  • Searchable by gene name or by text string
  • Browse the data
  • Download the datasets
  • Measure your favorite target
  • 60 cell line materials/data analysis provided
    free of charge
  • data to be made public on DTP web site
  • apply at http//dtp.nci.nih.gov/mtargets/targetee
    r.html

16
Mean Graphs
Compound
Molecular Target
17
COMPARECompounds vs. Molecular Targets
  • Positive correlations Cell lines with high
    levels of the Molecular Target are more sensitive
    to the compound.
  • Negative correlations Cell lines with low
    levels of the Molecular Target are more sensitive
    to the compound.

18
COMPARE drug-target success stories
  • CDK4-NSC 680434 (IC50 3.1 microM) Kubo et al.
    1999
  • EGFR and ErbB2 pathway inhibitors - 14 compounds
    Wosikowski et al. 1997
  • Identification of cellular receptor for AAV5
    virus, Pasquale et al. 2003
  • Sensitivity to a glycogen phosphylase inhibitor
    correlates with mRNA levels of GP, Schnier et al.
    2003

19
COMPARE Can Help Find Molecular Targets Important
in Drug Sensitivity
  • Transport of compound
  • Metabolism of compound
  • Pathways that may be affected by compound
  • Possible Molecular Target of compound

20
(No Transcript)
21
COMPARE Can Help Find Molecular Targets Important
in Drug Sensitivity
  • Transport of compound
  • Metabolism of compound
  • Pathways that may be affected by compound
  • Possible Molecular Target of compound

22
COMPARE Results for DT-Diaphorase Activity(a
quinone-metabolizing enzyme)
23
COMPARE Can Help Find Molecular Targets Important
in Drug Sensitivity
  • Transport of compound
  • Metabolism of compound
  • Pathways that may be affected by compound
  • Possible Molecular Target of compound

24
Diethyldithiocarbamate (NSC 4857 Et2NCS2H)-An
Inhibitor of NF-kappaB Higher levels of these
genes correlate with sensitivity
  • 1 0.51 nucleoporin-like protein 1
  • 7 0.41 TRAF family member-associated
  • NFKB activator
  • 11 0.4 acid sphingomyelinase
  • 16 0.39 phospholipase C, gamma 2
  • 38 0.35 interleukin 1 receptor, type II

25
Interleukin 1 SignalingDaun JM, Fenton MJJ
Interferon Cytokine Res 2000 Oct20(10)843-55
26
COMPARE Can Help Find Molecular Targets Important
in Drug Sensitivity
  • Transport of compound
  • Metabolism of compound
  • Pathways that may be affected by compound
  • Possible Molecular Target of compound

27
Cells With Higher Levels of erbB2 are Sensitive
to anti-erbB2 Immunotoxin
erbB2
28
COMPARE Results for 1,10-phenanthroline - An MMP
Inhibitor
A matrix metalloproteinase inhibitor
MMP9
29
PDGF receptor is the receptor for
adeno-associated virus 5
PDGFRa
30
COMPARE Not the Final Answer
  • COMPARE can provide a starting point for
    experiments, but is NOT the whole story.
  • Compounds and Targets with flat patterns can
    give strong correlations. Take a look at the
    data.
  • COMPARE at GI50, TGI and LC50 can give different
    answers.
  • Correlations with an mRNA target may be
    misleading if the gene product is
    post-transcriptionally regulated.

31
CONCLUSIONS
  • 60 cell line data for 40,000 compounds and
    10,000 Molecular Targets
  • Target data can be correlated with sensitivity to
    compounds
  • Other development resources
  • RAND
  • Molecular Targeted Assays
  • Compounds, extracts, cell lines, tumors
  • Data freely available at
  • http//dtp.nci.nih.gov

32
Thanks to the Targeteers
Carmen Allegra John Lazo Robert Shoemaker Susan
Bates Dick Leopold Norman Sladek David
Botstein Millennium Barbara Sosnowski Raymond
Budde Anne Monks Patricia Steeg Jay
Chiorini Jeffrey Moscow Sherman Stinson Michael
Dean Novartis Sugen Tito Fojo Patrick
O'Connor Yoshikazu Sugimoto Albert
Fornace Lawrence Panasci Kenneth Tew Steve
Friend Marcus Peter George Vande Woude Stanton
Gerson Garth Powis David Waxman Jean Grem John
Reed John Weinstein David Hyndman Joachim
Schnier Paul Workman Michael Kelley Daominic
Scudiero Guido Kroemer Michael Seiden
Write a Comment
User Comments (0)
About PowerShow.com